Topics

Developers request revocation of remdesivir’s ODD for COVID-19

12:30 EDT 26 Mar 2020 | European Pharmaceutical Review
coronavirus particles in yellow on a blue background

Gilead Sciences say they are confident they can maintain an expedited regulatory review timeline for remdesivir as a treatment for COVID-19 without Orphan Drug Designation (ODD).

The post Developers request revocation of remdesivir’s ODD for COVID-19 appeared first on European Pharmaceutical Review.

Original Article: Developers request revocation of remdesivir’s ODD for COVID-19

NEXT ARTICLE

More From BioPortfolio on "Developers request revocation of remdesivir’s ODD for COVID-19"

Quick Search

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...